Glucocorticoid Receptor-Deficient Foxp3 + Regulatory T Cells Fail to Control Experimental Inflammatory Bowel Disease

• Published in: Frontiers in immunology 2019-03, Vol.10, p.472-472
• Main Authors: Rocamora-Reverte, Lourdes, Tuzlak, Selma, von Raffay, Laura, Tisch, Marcel, Fiegl, Heidi, Drach, Mathias, Reichardt, Holger M, Villunger, Andreas, Tischner, Denise, Wiegers, G Jan
• Format: Article
• Language: English
• Subjects: Foxp3; glucocorticoid; glucocorticoid receptor; Immunology; regulatory T cell; suppression; transfer colitis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.00472

Activation of the immune system increases systemic adrenal-derived glucocorticoid (GC) levels which downregulate the immune response as part of a negative feedback loop. While CD4 T cells are essential target cells affected by GC, it is not known whether these hormones exert their major effects on CD4 helper T cells, CD4 Foxp3 regulatory T cells (Treg cells), or both. Here, we generated mice with a specific deletion of the glucocorticoid receptor (GR) in Foxp3 Treg cells. Remarkably, while basal Treg cell characteristics and suppression capacity were unchanged, Treg cells lacking the GR did not prevent the induction of inflammatory bowel disease in an mouse model. Under inflammatory conditions, GR-deficient Treg cells acquired Th1-like characteristics and expressed IFN-gamma, but not IL-17, and failed to inhibit pro-inflammatory CD4 T cell expansion . These findings reveal that the GR is critical for Foxp3 Treg cell function and suggest that endogenous GC prevent Treg cell plasticity toward a Th1-like Treg cell phenotype in experimental colitis. When equally active in humans, a rationale is provided to develop GC-mimicking therapeutic strategies which specifically target Foxp3 Treg cells for the treatment of inflammatory bowel disease.